prikaz prve stranice dokumenta Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer’s disease
  Preuzmi
PDF 5 MB
Znanstveni rad - Izvorni znanstveni rad
Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer’s disease
Neuropharmacology, 135 (2018); 48-62. https://doi.org/10.1016/j.neuropharm.2018.02.027
Knezović, Ana; Osmanović Barilar, Jelena; Babić, Ana; Bagarić, Robert; Farkaš, Vladimir; Riederer, Peter; Šalković-Petrišić, Melita

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Knezović, A., Osmanović Barilar, J., Babić, A., Bagarić, R., Farkaš, V., Riederer, P. i Šalković Petrišić, M. (2018). Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer’s disease. Neuropharmacology, 135., 48-62. doi: 10.1016/j.neuropharm.2018.02.027

Knezović, Ana, et al. "Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer’s disease." Neuropharmacology, vol. 135, 2018, str. 48-62. https://doi.org/10.1016/j.neuropharm.2018.02.027

Knezović, Ana, Jelena Osmanović Barilar, Ana Babić, Robert Bagarić, Vladimir Farkaš, Peter Riederer i Melita Šalković Petrišić. "Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer’s disease." Neuropharmacology 135 (2018): 48-62. https://doi.org/10.1016/j.neuropharm.2018.02.027

Knezović, A., et al. (2018) 'Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer’s disease', Neuropharmacology, 135, str. 48-62. doi: 10.1016/j.neuropharm.2018.02.027

Knezović A, Osmanović Barilar J, Babić A, Bagarić R, Farkaš V, Riederer P, i sur.. Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer’s disease. Neuropharmacology [Internet]. 06.2018. [pristupljeno 14.05.2024.];135:48-62. doi: 10.1016/j.neuropharm.2018.02.027

A. Knezović, et al., "Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer’s disease", Neuropharmacology, vol. 135, str. 48-62, Lipanj 2018. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:353238. [Citirano: 14.05.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:353238
Podaci o radu
Naslov (engleski)Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer’s disease
AutorAna Knezović
AutorJelena Osmanović Barilar
AutorAna Babić
AutorRobert Bagarić
AutorVladimir Farkaš
AutorPeter Riederer
AutorMelita Šalković-Petrišić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Sažetak (engleski)
Insulin resistance and metabolic dysfunction in the brain are considered to be the pathophysiological core of sporadic Alzheimer's disease (sAD). In line with that fact, nutrients that could have therapeutic effects at this level have been investigated as possible targets in AD therapy. Galactose, an epimer of glucose, may serve as an alternative source of energy, and given orally may stimulate secretion of the incretin hormone glucagon-like peptide-1 (GLP-1). Our preliminary research indicated that oral galactose might prevent development of memory impairment in a rat model of sAD generated by intracerebroventricular administration of streptozotocin (STZ-icv). Here, we explored whether chronic oral galactose treatment could have beneficial effects on cognitive deficits already manifested at the time of initiation of galactose treatment in adult STZ-icv rats (treatment initiated 1 month after STZ-icv injection). The results clearly show that a 2-month exposure to oral galactose (200 mg/kg/day administered in a drink ad libitum) normalises impaired learning and memory functions. Memory improvement was accompanied by an improvement in brain glucose hypometabolism measured by 18fluorodeoxyglucose-positron emission tomography neuroimaging and by increments in active GLP-1 plasma levels as well as by an increased expression of GLP-1 receptors in the hippocampus and hypothalamus. Our findings provide strong evidence of beneficial effects of oral galactose treatment in the STZ-icv rat model of sAD and present possible underlying mechanisms including both direct effects of galactose within the brain and indirect GLP-1-induced neuroprotective effects that might open a new, dietary-based strategy in sAD treatment.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeZavršna verzija rukopisa prihvaćena za objavljivanje (postprint)
Naslov časopisaNeuropharmacology
Brojčani podacivol. 135, str. 48-62
p-ISSN0028-3908
DOIhttps://doi.org/10.1016/j.neuropharm.2018.02.027
URN:NBNurn:nbn:hr:105:353238
Datum objave publikacije2018-06
URL dokumentahttps://doi.org/10.1016/j.neuropharm.2018.02.027
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-28 10:14:44